Vergoeding 2016-2020 voor ATC-subgroep L04AA : Selectieve immunosuppressiva
- Raming voor de totale Zvw-populatie
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| L04AA06 Mycofenolzuur (Cellcept ®) | 10.999.300 | 11.030.400 | 10.950.000 | 11.724.700 | 11.511.500 |
| L04AA10 Sirolimus (Rapamune ®) | 1.520.200 | 1.454.800 | 1.458.200 | 1.484.900 | 1.429.600 |
| L04AA13 Leflunomide (Arava ®) | 1.995.400 | 1.924.600 | 2.039.400 | 2.329.200 | 1.075.300 |
| L04AA18 Everolimus (Certican ®) | 4.053.400 | 4.297.000 | 4.946.800 | 5.243.600 | 4.731.400 |
| L04AA27 Fingolimod (Gilenya ®) | 22.922.700 | 24.380.400 | 27.140.800 | 27.440.900 | 24.571.600 |
| L04AA31 Teriflunomide (Aubagio ®) | 8.508.200 | 10.976.800 | 12.681.800 | 14.037.300 | 14.724.200 |
| L04AA38 Ozanimod (Zeposia ®) | . | . | . | . | 1.441 |
| L04AA40 Cladribine (Mavenclad ®) | . | . | 2.290.500 | 4.663.800 | 3.922.100 |
| Totaal | 49.999.200 | 54.064.000 | 61.507.500 | 66.924.400 | 61.967.141 |